Form 4: Century Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock at an average price of $2.9978 under a pre-arranged trading plan.

Summary

• Gregory Russotti, the Chief Technology and Manufacturing Officer of Century Therapeutics, sold 5,000 shares of common stock on June 5, 2024.
• The sale was executed at a weighted average price of $2.9978 per share, with individual transactions ranging from $2.895 to $3.06.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on January 9, 2024.
• Following the transaction, Russotti directly owns 282,319 shares and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance, but are closely watched by investors for signals about the company's prospects. Sales under 10b5-1 plans are generally viewed as less concerning since they are pre-arranged.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates